A carregar...
Publicação
Vitrolife private equity investment committee paper - business plan
| Nome: | Descrição: | Tamanho: | Formato: | |
|---|---|---|---|---|
| 37.68 MB | Adobe PDF |
Autores
Orientador(es)
Resumo(s)
The target company, Vitrolife provides Medical Consumables, Technological Devices (C&T)
and Genetic Testing services (GT) for in-vitro fertilization. C&T has a market size of SEK 15bn
(CAGR of 14.3%) while GT’s market size is SEK 41bn (CAGR of 6.7%). Value creation is
driven through an AI software partnership, the Eastern Europe Penetration and the acquisition
of Virtus Health. Most of the value is driven by inorganic growth (50%). Based on a 16.7x exit
multiple and an Enterprise Value of SEK 17,250m, a MM of 3.6x can be realized over the
holding period. Sources of funds include SEK 5,693m (5.5x) debt and SEK 12,418m (12x)
equity.
Descrição
Palavras-chave
Private equity Acquisition Vitrolife Leveraged buyout